Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin

Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators

(2014) Lyndsay V. Rhodes et al.   BREAST CANCER RESEARCH AND TREATMENT

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling

(2014) Paola Marcato et al.   Molecular Oncology

Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights

(2014) Prithviraj Bose et al.   PHARMACOLOGY & THERAPEUTICS

Histone deacetylase inhibitors

(2013) Marije Slingerland et al.   ANTI-CANCER DRUGS

Salinomycin induces apoptosis and senescence in breast cancer: Upregulation of p21, downregulation of survivin and histone H3 and H4 hyperacetylation

(2013) Yusra Al Dhaheri et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Clinical–pathologic significance of cancer stem cell marker expression in familial breast cancers

(2013) Anita Bane et al.   BREAST CANCER RESEARCH AND TREATMENT

HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells

(2013) Laurence Booth et al.   CANCER BIOLOGY & THERAPY

ALDH1-Positive Cancer Stem Cells Predict Engraftment of Primary Breast Tumors and Are Governed by a Common Stem Cell Program

(2013) E. Charafe-Jauffret et al.   CANCER RESEARCH

FOXC2 Expression Links Epithelial-Mesenchymal Transition and Stem Cell Properties in Breast Cancer

(2013) B. G. Hollier et al.   CANCER RESEARCH

The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression

(2013) M. A. Salvador et al.   CLINICAL CANCER RESEARCH

Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells

(2012) Che-Hsin Lee et al.   BIOCHIMIE

Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer

(2012) Julia Y. S. Tsang et al.   BREAST CANCER RESEARCH AND TREATMENT

Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)

(2012) Makoto Kubo et al.   BREAST CANCER RESEARCH AND TREATMENT

Mesenchymal–epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer

(2012) N. P. A. Devika Gunasinghe et al.   CANCER AND METASTASIS REVIEWS

Cancer Epigenetics: From Mechanism to Therapy

(2012) Mark A. Dawson et al.   CELL

Breast Cancer Stem Cells: A Novel Therapeutic Target

(2012) Sudeshna Gangopadhyay et al.   Clinical Breast Cancer

Salinomycin as a Drug for Targeting Human Cancer Stem Cells

(2012) Cord Naujokat et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells

(2012) R. Rao et al.   MOLECULAR CANCER THERAPEUTICS

Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/β-Catenin Signaling

(2012) Bisrat G. Debeb et al.   STEM CELLS

Salinomycin - A New Cancer Drug Candidate

(2011) Adam Huczynski   Chemical Biology & Drug Design

The wnt/β-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer

(2011) Taj D. King et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Twist2 contributes to breast cancer progression by promoting an epithelial–mesenchymal transition and cancer stem-like cell self-renewal

(2011) X Fang et al.   ONCOGENE

Management of triple negative breast cancer

(2010) Catherine Oakman et al.   BREAST

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Triple-negative breast cancer: disease entity or title of convenience?

(2010) Lisa Carey et al.   Nature Reviews Clinical Oncology

The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression

(2010) S. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

(2010) Julia M. Wagner et al.   Clinical Epigenetics

Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment

(2009) Erika Resetkova et al.   BREAST CANCER RESEARCH AND TREATMENT

Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

(2009) Peter Atadja   CANCER LETTERS

Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature

(2009) Emmanuelle Charafe-Jauffret et al.   CANCER RESEARCH

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening

(2009) Piyush B. Gupta et al.   CELL

Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer

(2009) Carey K. Anders et al.   Clinical Breast Cancer

Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance

(2009) Rosaria Gangemi et al.   CURRENT MEDICINAL CHEMISTRY

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

(2008) Sendurai A. Mani et al.   CELL

Triple-Negative Breast Cancer: Risk Factors to Potential Targets

(2008) B. P. Schneider et al.   CLINICAL CANCER RESEARCH

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

(2008) X. Li et al.   JNCI-Journal of the National Cancer Institute

BRCA1 regulates human mammary stem/progenitor cell fate

(2008) S. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA